Ultomiris™(ravulizumab-cwvz) – New orphan drug approval
December 21, 2018 - The FDA announced the approval of Alexion Pharmaceuticals’ Ultomiris (ravulizumab-cwvz), for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Download PDF
